Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2573488 | 0.84 | TLR7 (0.73) | TLR7ADORA1HPGD | |
| SCHEMBL2569278 | 0.81 | TLR7 (0.68) | TLR7ADORA1KDM4EMEN1PSMD14 | |
| SCHEMBL29454517 | 0.81 | TLR7 (1.00) | TLR7 | |
| SCHEMBL2569145 | 0.81 | TLR7 (1.00) | TLR7 | |
| SCHEMBL29454518 | 0.81 | TLR7 (1.00) | TLR7 | |
| SCHEMBL12164383 | 0.80 | TLR7 (0.67) | TLR7KDM4EMEN1PSMD14HPGD | |
| SCHEMBL2568873 | 0.80 | TLR7 (0.67) | TLR7ADORA1HPGD | |
| SCHEMBL2573444 | 0.80 | TLR7 (0.78) | TLR7 | |
| SCHEMBL2571238 | 0.80 | TLR7 (0.66) | TLR7 | |
| SCHEMBL2571349 | 0.80 | TLR7 (0.65) | TLR7ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | disclosed |
| EP-1987030-B1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LTD (GB) | 2011-11-09 | — | — | EP | disclosed |
| US-7691877-B2 | Pharmaceuticals | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691877-B2 | Pharmaceuticals | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691877-B2 | Pharmaceuticals | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1987030-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | Pfizer Limited (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093901-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093901-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | PFIZER LIMITED | 2007-08-23 | — | — | US | disclosed |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | PFIZER LIMITED | 2007-08-23 | — | — | US | disclosed |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | PFIZER LIMITED | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | TLR3, HAVCR2, TLR9 | TLR7 7/4885ADORA1 505/4885KDM4E 2698/4885 |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | TLR3, TLR7, TLR8 | TLR7 2/4885ADORA1 660/4885KDM4E 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.